IBTROZI’s 89.8% Response Rate Is a Launch Story — The Real Prize Is What Comes After First-Line
Nuvation Bio's IBTROZI hit $18.5M in Q1 2026 revenue with 600+ patients on drug. The first-line TKI-naïve data makes...
ROS1-positive NSCLC
Nuvation Bio's IBTROZI hit $18.5M in Q1 2026 revenue with 600+ patients on drug. The first-line TKI-naïve data makes...